Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dexamethasone-Eluting Cochlear Implant Electrode (CIDEX)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04450290
Recruitment Status : Recruiting
First Posted : June 29, 2020
Last Update Posted : July 7, 2020
Sponsor:
Information provided by (Responsible Party):
MED-EL Elektromedizinische Geräte GesmbH

Brief Summary:

A newly developed MED-EL Cochlear Implant incorporates the anti-inflammatory agent dexamethasone (DEX) into the electrode array. The passive elution of DEX during the post-implantation period has the purpose of counteracting the increase of the post-operative impedance induced by the insertion trauma.

The aim of this clinical investigation is to obtain a first experience in use of the investigational device in the adult clinical population, and to initially assess tools, techniques and performance outcome measures that may be considered in future clinical studies of similar devices.


Condition or disease Intervention/treatment Phase
Hearing Loss, Sensorineural Sensorineural Hearing Loss Device: CIDEXEL implant Not Applicable

Detailed Description:

The principal objective of this study is to exploratively investigate the safety profile of the device which will be evaluated through the analysis of adverse events during the follow-up period. For the study to be considered a success, the results of the adverse event analysis shall never cause an unbalanced risk vs. benefit assessment.

The secondary objectives of this study aim at investigating the usefulness of possible outcome measures in evaluating the performance of the device.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: First-in-human, single-arm, exploratory, open-label, prospective, longitudinal, monocentric study
Masking: None (Open Label)
Primary Purpose: Device Feasibility
Official Title: Dexamethasone-Eluting Cochlear Implant Electrode (CIDEXEL): A First in Human Study
Actual Study Start Date : June 30, 2020
Estimated Primary Completion Date : July 1, 2021
Estimated Study Completion Date : July 1, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: single arm - treatment
All subjects will be implanted with the investigational device.
Device: CIDEXEL implant
The newly developed MED-EL Cochlear Implant incorporates the anti-inflammatory agent dexamethasone (DEX) into the electrode array. The passive elution of DEX during the post-implantation period has the purpose of counteracting the increase of the post-operative impedance induced by the insertion trauma.




Primary Outcome Measures :
  1. Adverse Events [ Time Frame: 10 months ]
    Safety profile of the device which will be evaluated through the analysis of adverse events


Secondary Outcome Measures :
  1. IFT (Impedance Field Telemetry) - impedance [ Time Frame: 10 months ]
    Impedance Field Telemetry and derived values

  2. Electrically Evoked Compound Action Potential [ Time Frame: 10 months ]
    Electrically Evoked Compound Action Potential and derived values

  3. MCL (Maximum Comfortable Loudness) [ Time Frame: 10 months ]
    Maximum Comfortable Loudness Levels and Thresholds

  4. THR (Threshold) [ Time Frame: 10 months ]
    Thresholds

  5. PTA (Pure Tone Audiometry) Audiometrical values [ Time Frame: 10 months ]
    Results from PTA assessment

  6. Hearing Preservation rate [ Time Frame: 10 months ]
    Rate of Hearing Preservation according to Skarżyński et al.

  7. HSM (Hochmair-Schulz-Moser Sentence) Test [ Time Frame: 10 months ]
    Speech test in noise

  8. Questionnaire [ Time Frame: 10 months ]
    Surgical feedback questionnaire



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Minimum age of eighteen (18) years at time of enrolment.
  • Severe to profound sensorineural hearing loss on the ipsilateral ear.
  • A functional auditory nerve in the ear to be implanted.
  • Subjects reporting to having used an optimally fit hearing aids for a minimum of three months before the decision that a cochlear implant (CI) is the preferential option.
  • Cochlea anatomy compatible with the insertion of a +FLEX28 electrode array.
  • Compatibility with a soft surgery approach as per clinical practice at the site.
  • Post-lingual hearing impairment.
  • Subject fulfilling indication criteria for a CI according to the local professional standards, as reported by the implanting surgeon.
  • General health condition, psychological and emotional condition deemed compatible with the treatment and tests performed in this study and realistic expectations, as deemed appropriate by the implanting surgeon.
  • Signed and dated informed consent before the start of any study-specific procedure.

Exclusion Criteria:

  • Lack of compliance with any inclusion criterion.
  • Previously having received a cochlear implant on the ear chosen for placing the IMD (Investigational Medical Device).
  • Evidence of ossification or any other cochlear anomaly that might prevent complete insertion of the electrode array or might cause increased risk of infection (e.g. dysplastic cochlea), as confirmed by medical examination and/or as per CT/MRT (Computed Tomography/Magnetic Resonance Tomography).
  • Evidence of anatomic abnormalities that would prevent appropriate placement of the stimulator housing in the bone of the skull.
  • Evidence of otosclerosis.
  • Known allergic reaction or intolerance to the materials used in the implant (including medical grade silicone, platinum, iridium, parylene c, dexamethasone).
  • Known absence of cochlear development or if the cause of deafness is non-functionality of the auditory nerve and/or the upper auditory pathway.
  • Evidence of active external or middle ear infection or history of recurrent middle ear infection in the ear to be implanted.
  • Evidence of perforated tympanic membrane in the ear to be implanted.
  • Patient reporting immunosuppressive therapy or corticosteroids therapy in the 4 weeks before enrolment.
  • Evidence of concomitant use of medicinal substances that, in the opinion of the investigator, could alter the therapeutic efficacy of dexamethasone.
  • Unwillingness or inability of the candidate to comply with all investigational requirements.
  • Evidence of medical contraindications to surgery of the middle and inner ear and anaesthesia.
  • Additional disabilities that would prevent or restrict participation in the audiological and medical evaluations required of the clinical investigation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04450290


Contacts
Layout table for location contacts
Contact: Stefano Morettini 0043577885591 stefano.morettini@medel.com

Locations
Layout table for location information
Germany
MHH - Medizinische Hochschule Hannover Recruiting
Hannover, Germany, 30625
Contact: Thomas Lenarz, Prof. Dr.    +49051532      
Sponsors and Collaborators
MED-EL Elektromedizinische Geräte GesmbH
Investigators
Layout table for investigator information
Principal Investigator: Thomas Lenarz, Prof. Prof. h. c. Dr. med. Hals-Nasen-Ohrenklinik der Medizinischen Hochschule Hannover
Layout table for additonal information
Responsible Party: MED-EL Elektromedizinische Geräte GesmbH
ClinicalTrials.gov Identifier: NCT04450290    
Other Study ID Numbers: MED-EL_CRD_2014_02
First Posted: June 29, 2020    Key Record Dates
Last Update Posted: July 7, 2020
Last Verified: July 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hearing Loss
Deafness
Hearing Loss, Sensorineural
Hearing Disorders
Ear Diseases
Otorhinolaryngologic Diseases
Sensation Disorders
Neurologic Manifestations
Nervous System Diseases